Logo Image
Opinion|Videos|September 18, 2024

Fruquintinib in mCRC: Key Insights From FRESCO-2

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Episodes in this series

Video content above is prompted by the following:

  1. New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
  2. Include in this discussion that all patients previously received regorafenib or FTD/TPI.
  3. What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?

Related Content